Detalhe da pesquisa
1.
The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan.
Lancet Oncol
; 25(1): e6-e17, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37977167
2.
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study.
Lancet Oncol
; 25(5): 636-648, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621404
3.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342115
4.
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Breast Cancer Res Treat
; 205(2): 349-358, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244167
5.
Blocking channels to metastasis: targeting sodium transport in breast cancer.
Breast Cancer Res
; 25(1): 140, 2023 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950273
6.
Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.
PLoS Med
; 20(1): e1004086, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36719907
7.
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Br J Cancer
; 129(5): 852-860, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468569
8.
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Oncologist
; 28(4): 319-326, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866462
9.
1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.
Planta Med
; 88(2): 163-178, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33445186
10.
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.
Breast J
; 2022: 7146172, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833190
11.
The genomic landscape of breast cancer brain metastases: a systematic review.
Lancet Oncol
; 22(1): e7-e17, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387511
12.
Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
Breast Cancer Res
; 23(1): 33, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33736675
13.
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Oncologist
; 26(10): 835-844, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105210
14.
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
Breast Cancer Res Treat
; 190(2): 241-253, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499316
15.
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Breast Cancer Res
; 22(1): 126, 2020 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33198803
16.
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Breast Cancer Res Treat
; 175(1): 149-163, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680659
17.
Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Breast Cancer Res Treat
; 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704774
18.
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Breast Cancer Res Treat
; 167(1): 407, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29071491
19.
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Nature
; 481(7381): 389-93, 2012 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-22217937
20.
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Breast Cancer Res Treat
; 165(2): 343-353, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28612226